Arg-Pro-Leu-Lys-Pro-Trp
has antihypertensive activity
Also Known As:
RPLKPW peptide; arginyl-prolyl-leucyl-lysyl-prolyl-tryptophan; novokinin
Networked: 5
relevant articles (2 outcomes,
2 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Experts
1. | Bhavsar, Riya:
1 article
(06/2019)
|
2. | Kurade, Mangesh:
1 article
(06/2019)
|
3. | Mustafa, S Jamal:
1 article
(06/2019)
|
4. | Patel, Mehaben:
1 article
(06/2019)
|
5. | Ponnoth, Dovenia S:
1 article
(06/2019)
|
6. | Rajalingam, Sahith:
1 article
(06/2019)
|
7. | Grozdanov, P:
1 article
(05/2018)
|
8. | Nenchovska, Z:
1 article
(05/2018)
|
9. | Pechlivanova, D:
1 article
(05/2018)
|
10. | Petrov, K:
1 article
(05/2018)
|
Related Diseases
1. | Hypertension (High Blood Pressure)
06/23/2016
- " Although further studies are needed to determine its effectiveness, the AT2 agonist novokinin may be a novel agent that is promising in terms of protective effects for the treatment of hypertension." 06/23/2016
- " The effects of novokinin, an AT2 agonist, on blood pressure, vascular responses, and levels of ADMA, NADPH oxidase, and Rho kinase in hypertension induced by NOS inhibition and salt." 06/23/2016
- " The effects of AT2 receptor agonist novokinin on blood pressure, eNOS, NADPH oxidase, protein arginine methyltransferases (PRMTs), and Rho kinase in hypertension were investigated. "
|
2. | Hyperalgesia
|
3. | Asthma (Bronchial Asthma)
|
4. | Ulcer
|
5. | Diabetes Mellitus
|
|
Related Drugs and Biologics
Related Therapies and Procedures